Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab for Relapsed AML and MDS Post-Allo-HCT
NCT04582864Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants With CR(Mrd), CR, and CRi. Started May 2021; status: terminated.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04582864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582864.